Navann Ty

Stock Analyst at Exane BNP Paribas

(3.20)
# 2,582
Out of 4,639 analysts
39
Total ratings
55.6%
Success rate
7.4%
Average return

Stocks Rated by Navann Ty

Organon & Co.
Apr 28, 2026
Downgraded: Hold
Price Target: $15$14
Current: $13.65
Upside: +2.56%
Medline
Jan 12, 2026
Initiated Coverage: Hold
Price Target: $38
Current: $35.04
Upside: +8.45%
Natera
Oct 27, 2025
Upgraded: Hold
Price Target: $28$172
Current: $312.72
Upside: -45.00%
GE HealthCare Technologies
Sep 10, 2025
Reiterated: Buy
Price Target: $92
Current: $72.75
Upside: +26.46%
Phibro Animal Health
Sep 4, 2025
Maintained: Hold
Price Target: $24$37
Current: $34.08
Upside: +8.57%
The Cooper Companies
Jul 22, 2025
Upgraded: Buy
Price Target: $92
Current: $76.82
Upside: n/a
Kenvue
May 30, 2023
Initiated Coverage: Hold
Price Target: $28
Current: $19.05
Upside: n/a
SkinHealth Systems
Mar 20, 2023
Upgraded: Hold
Price Target: n/a
Current: $0.70
Upside: n/a
AbbVie
Dec 8, 2022
Initiated Coverage: Hold
Price Target: $169
Current: $250.09
Upside: n/a
Evolus
Dec 8, 2022
Initiated Coverage: Buy
Price Target: $13
Current: $8.34
Upside: n/a
Maintained: Hold
Price Target: $22$26
Current: $49.21
Upside: n/a
Maintained: Hold
Price Target: $16$11
Current: $16.28
Upside: n/a
Maintained: Hold
Price Target: $232$208
Current: $75.35
Upside: n/a
Initiated Coverage: Buy
Price Target: $200
Current: $247.98
Upside: n/a
Maintained: Buy
Price Target: $39$42
Current: $22.73
Upside: n/a
Maintained: Buy
Price Target: $36.28$51.63
Current: $8.68
Upside: n/a
Initiated Coverage: Hold
Price Target: $10
Current: $36.48
Upside: n/a